Clearside Biomedical, Inc.
CLSDQ
$0.95
$0.1215.14%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -80.64% | 446.67% | 913.04% | -95.18% | 20.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -80.64% | 446.67% | 913.04% | -95.18% | 20.84% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -80.64% | 446.67% | 805.22% | -97.53% | 44.77% |
| SG&A Expenses | 51.48% | -19.53% | 0.00% | 3.90% | 7.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.86% | -47.14% | -10.71% | -19.49% | -11.89% |
| Operating Income | -18.64% | 52.99% | 36.59% | -145.25% | 15.88% |
| Income Before Tax | 22.32% | 40.81% | 36.17% | -51.20% | 17.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.32% | 40.81% | 30.09% | -51.20% | 17.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.32% | 40.81% | 30.09% | -51.20% | 17.04% |
| EBIT | -18.64% | 52.99% | 36.59% | -145.25% | 15.88% |
| EBITDA | -18.72% | 53.83% | 37.42% | -144.21% | 16.75% |
| EPS Basic | 26.04% | 43.17% | 36.52% | -24.39% | 31.20% |
| Normalized Basic EPS | 26.05% | 43.18% | 42.03% | -24.40% | 31.20% |
| EPS Diluted | 26.04% | 43.17% | 36.52% | -24.39% | 31.20% |
| Normalized Diluted EPS | 26.05% | 43.18% | 42.03% | -24.40% | 31.20% |
| Average Basic Shares Outstanding | 5.04% | 4.16% | 10.12% | 21.55% | 20.59% |
| Average Diluted Shares Outstanding | 5.04% | 4.16% | 10.12% | 21.55% | 20.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |